1. American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep. 2003. 52:1–77.
2. Bai GH. Anti-tuberculosis drug resistance in Korea. Commun Dis Month Rep. 2005. 16:101–107.
3. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis. 1986. 133:423–430.
4. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis. 1989. 140:1189–1193.
5. Grosset J, Truffot-Pernot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination pyrazinamiderifampin against tuberculosis infection in mice. Antimicrob Agents Chemother. 1992. 36:548–551.
6. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med. 2003. 167:1348–1354.
7. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med. 2004. 169:421–426.
8. Rosenthal IM, Williams K, Tyagi S, Vernon AA, Peloquin CA, Bishai WR, et al. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med. 2005. 172:1457–1462.
9. Roberts AD, Cooper AM, Beslisle JT, Turner J, Gonzalez-Juarrero M, Orme IM. Kaufmann SHE, Kabelitz D, editors. Murine model of tuberculosis. Methods in microbiology. 2002. 32. New York: Elsevier Sciences;433.
10. Nuermberger E, Rosenthal I, Tyagi S, Williams KN, Almeida D, Peloquin CA, et al. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother. 2006. 50:2621–2625.
11. Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep. 2001. 50:289–291.
12. Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep. 2003. 52:735–739.
13. Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2002. 51:998–999.